Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, Sidders B, Corbau R, Pickford C, Murray EJ. Laxton C, et al. Among authors: brady k. Antimicrob Agents Chemother. 2011 Jul;55(7):3105-14. doi: 10.1128/AAC.00222-11. Epub 2011 Apr 18. Antimicrob Agents Chemother. 2011. PMID: 21502629 Free PMC article.
In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy.
Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H, Palmer A, Perkins H, Savic B, Scott S, Smith-Burchnell C, Troke P, Wright JF, Suhy D, Corbau R. Lavender H, et al. Among authors: brady k. Antimicrob Agents Chemother. 2012 Mar;56(3):1364-75. doi: 10.1128/AAC.05357-11. Epub 2011 Dec 27. Antimicrob Agents Chemother. 2012. PMID: 22203606 Free PMC article.
Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.
Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, Weber M, Lazari O, Perez-Tosar L, Fancy SA, Lapthorn C, Green MX, Evans S, Selby M, Jones G, Jones L, Kearney S, Mechiche H, Gikunju D, Subramanian R, Uhlmann E, Jurk M, Vollmer J, Ciaramella G, Yeadon M. Moschos SA, et al. Among authors: brady k. Mol Ther. 2011 Dec;19(12):2163-8. doi: 10.1038/mt.2011.206. Epub 2011 Oct 4. Mol Ther. 2011. PMID: 21971426 Free PMC article.
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.
Suhy DA, Kao SC, Mao T, Whiteley L, Denise H, Souberbielle B, Burdick AD, Hayes K, Wright JF, Lavender H, Roelvink P, Kolykhalov A, Brady K, Moschos SA, Hauck B, Zelenaia O, Zhou S, Scribner C, High KA, Renison SH, Corbau R. Suhy DA, et al. Among authors: brady k. Mol Ther. 2012 Sep;20(9):1737-49. doi: 10.1038/mt.2012.119. Epub 2012 Jun 26. Mol Ther. 2012. PMID: 22735378 Free PMC article.
Kappa agonist CovX-Bodies.
Roberts LR, Brady K, Brown A, Davey D, Feng L, Huang H, Liu D, Malet L, McMurray G, Phelan A, Saunders K, Bhat A. Roberts LR, et al. Among authors: brady k. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4173-8. doi: 10.1016/j.bmcl.2012.04.040. Epub 2012 Apr 25. Bioorg Med Chem Lett. 2012. PMID: 22583618
Localized eruption of glabella and eyebrows.
Okoye C, Brady K, Shastry J. Okoye C, et al. Among authors: brady k. JAAD Case Rep. 2024 Aug 31;53:37-39. doi: 10.1016/j.jdcr.2024.08.008. eCollection 2024 Nov. JAAD Case Rep. 2024. PMID: 39430639 Free PMC article. No abstract available.
Oxytocin moderates fMRI connectivity and response to implicit threat processing in cocaine use disorder.
Blidy KP, Bustos N, Spalten J, Crum KI, Jarnecke AM, Flanagan JC, Baker NL, Moran Santa-Maria M, Hartwell KJ, Brady KT, McRae-Clark AL, Joseph JE. Blidy KP, et al. Among authors: brady kt. Psychoneuroendocrinology. 2025 Jan;171:107217. doi: 10.1016/j.psyneuen.2024.107217. Epub 2024 Oct 10. Psychoneuroendocrinology. 2025. PMID: 39413528 Clinical Trial.
Development and Content Validation of the Patient's Qualitative Assessment of Treatment - Real-World (PQAT-RW): An Instrument to Evaluate Benefits and Disadvantages of Treatments in Real-World Settings.
Roborel de Climens A, Findley A, Bury DP, Brady KJS, Reaney M, Gater A. Roborel de Climens A, et al. Among authors: brady kjs. Patient Relat Outcome Meas. 2024 Oct 7;15:255-269. doi: 10.2147/PROM.S468623. eCollection 2024. Patient Relat Outcome Meas. 2024. PMID: 39399824 Free PMC article.
1,122 results